Diagnostic information specialist Quest Diagnostics (NYSE:DGX) will acquire the lab-related clinical outreach service operations of California-based hospital system Dignity Health, serving doctors and patients in parts of California and Nevada.
Outreach services are provided by hospitals to physicians and patients outside of a hospital setting.
Quest Diagnostics expects the transaction to be completed in June and anticipates it will be neutral to adjusted earnings in 2013 and modestly accretive to earnings per share in 2014. The company expects it to contribute about half a percentage point to consolidated revenues annually.
Quest Diagnostics president and CEO Steve Rusckowski said, "This acquisition is consistent with our five-point strategy, which includes delivering disciplined capital deployment and driving 1% to 2% in growth per year through strategically aligned fold-in acquisitions."
If completed, this will mark the second acquisition by Quest of an outreach business in 2013. In January, Quest acquired the clinical and anatomic-pathology outreach laboratory businesses of Massachusetts-based UMass Memorial Medical Center.
Additional terms of the Dignity Health acquisition were not disclosed.
Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Dividend Stocks in Gene Sequencing
Looking for dividend stocks in the gene sequencing field? Check out General Electric, Roche, and Quest Diagnostics.
IBM's Watson Is Tackling Medicine's Most Complex Problems
Some of the biggest companies in medicine are enlisting IBM to help solve medicine's toughest problems with Watson AI.
Better Buy: Exact Sciences Corporation vs. Quest Diagnostics
Does recent news for Exact Sciences make it a better buy now than this diagnostic industry heavyweight?